Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New state-of-the-art research facilities in Oxford will help enhance the treatment of musculoskeletal injuries, strengthen the fight against bone cancer and improve arthritis care.

Research teams have moved into the £6m “phase 2” of the Botnar Research Centre, based on the Nuffield Orthopaedic Centre site.

It makes the Oxford University research facility one of the largest musculoskeletal research centres in Europe, doubling its size to ensure it continues to compete with leading institutions on the world stage.

Phase 2 is the culmination of a seven year fundraising campaign by the NOC Appeal, the same independent charity that previously raised more than £5m to build the original Botnar Research Centre.

NOC Appeal director Jeanette Franklin, who was made an MBE for her work fundraising work, said: “This is a dream. It started back in the early 1990s when we set a target of raising £1m towards building the first phase of the Botnar. That became £5m and the centre opened its doors in 2002. Our vision always included a second phase and it is wonderful to see research teams moving in.”

The Botnar Research Centre now comprises 4,000sqm of custom built research facilities including state-of-the-art laboratories, flexible office accommodation and dedicated “write up” areas.

It can house up to 250 scientists, clinicians and support staff carrying out pioneering research in to conditions such as osteoporosis, osteoarthritis and cancer.  Research will include genetics and cell biology, orthopaedic engineering and surgery, clinical research and epidemiological studies.

It will also house research carried out by the National Institute for Health Research Oxford Biomedical Research Unit (Oxford BRU), a collaboration between Oxford University NHS Hospitals Trust and Oxford University to accelerate innovation in musculoskeletal research.

The opening of phase 2 of the Botnar Research Centre also marks the start of an exciting year for musculoskeletal research and treatment in Oxford.

This autumn, the Kennedy Institute of Rheumatology will open its new building at the University’s neighbouring Old Road campus. The institute, founded in 1965, transferred to Oxford University in 2011.

The Kennedy Institute, the Botnar Research Centre, and the Nuffield Orthopaedic Centre, will bring together world class basic research, translational research and NHS treatment at one location.

Professor Andy Carr, Divisional Director at the NOC and Director of the Botnar Research Centre and the NIHR Oxford BRU said: “Since it opened in 2002, the Botnar Research Centre has established itself as a world leading centre for musculoskeletal research. This annexe will strengthen our efforts and provide our researchers and clinicians with the best possible facilities”.

“We would like to say thank you to all those who contributed to the magnificent fundraising campaign that has made this world-class facility a reality.  Their hard work will help us improve the quality of life for those people who suffer from debilitating musculoskeletal conditions such as arthritis and osteoporosis.”

Links:

Botnar Research Centre


Watch: BBC News

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.